Alnylam LNP delivery platform receives NoA from USPTO
Alnylam Pharmaceuticals has received notice of allowance (NoA) from US Patent and Trademark Office (USPTO) for new patent covering second generation lipid nanoparticle (LNP) platform, including the MC3 lipid.
The patent application includes 30 claims covering composition of matter and formulations of MC3, as well as methods of using these compositions and formulations.
This second generation LNP delivery platform is being utilized in development programs as part of the company's Alnylam 5x15 product strategy.
The LNP delivery platform is used in ALN-TTR02, for the treatment of transthyretin-mediated amyloidosis (ATTR); ALN-PCS, for the treatment of severe hypercholesterolemia; and potentially other programs.
Alnylam senior vice president and chief business officer Laurence Reid said LNPs exhibit significant improvements in potency and therapeutic index for RNAi therapeutics, as evidenced by human data with ALN-PCS.
"These novel LNPs also define Alnylam's LNP platform for advancement of ALN-TTR02 and potentially other 'Alnylam 5x15' programs," Reid added.
Related Insight
Suppliers Directory
GOEBEL Instrumentelle Analytik - Complete Solutions in HPLC and UV/VIS Spectrophotometry
GOEBEL Instrumentelle Analytik offers complete solutions in HPLC and UV/VIS Spectrophotometry.
Production & Manufacturing > Process & Production > Suppliers
IKA® - Global Leaders in Mixing Technology
The IKA® Group is a global market leader for laboratory equipment, analytical and process technology. Magnetic stirrers, overhead stirrers, dispersers, shakers, mills, rotary evaporator, calorimeters, laboratory reactors and incubation shakers make up the laboratory and analytical equipment portfolio.
Production & Manufacturing > Process & Production > Suppliers
Applikon Biotechnology – Advanced Bioreactor Systems
Applikon Biotechnology is a world leader in developing and supplying advanced bioreactor systems from laboratory scale to production scale for the biotech and pharmaceutical market.
Production & Manufacturing > Process & Production > Suppliers
Production & Manufacturing
Fine & Speciality Chemicals
Manufacturing
Process & Production
OTC
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Process & Production Intelligence
Hydrogenation & Catalysis Tools
Published by HEL Group
Production & Manufacturing > Process & Production > White Papers
Buy the latest industry research online today!
Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Buy online from $3500
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Buy online from $3500
Comments may be moderated for spam, obscenities or defamation.